AN IN SILICO SIMULATION STUDY OF EXTENDED INTERVAL DOSING OF ATEZOLIZUMAB USING POPULATION PHARMACOKINETICS

被引：0
|
作者：
Peer, C. [1 ]
Schmidt, K. [1 ]
Arisa, O. [1 ]
Richardson, W. [1 ]
Paydary, K. [2 ]
Goldstein, D. [3 ,4 ,5 ]
Figg, W. [1 ]
Ratain, M. [2 ]
机构：
[1] Natl Canc Inst, Bethesda, MD USA
[2] Univ Chicago, Chicago, IL USA
[3] Tel Aviv Univ, Tel Aviv, Israel
[4] Rabin Med Ctr, Davidoff Canc Ctr, Tel Aviv, Israel
[5] Clalit Hlth Serv, Tel Aviv, Israel
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-036
引用
收藏
页码：S25 / S26
页数：2
相关论文
共 50 条
  • [31] Natalizumab extended-interval dosing in a real-life context: efficacy study
    Jeantin, L.
    De la Motte, M. Boudot
    Chauvin, M.
    Dade, M.
    Deschamps, R.
    Gueguen, A.
    Mossad, M.
    Diallo, S. S.
    Gout, O.
    Bensa, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 852 - 853
  • [32] POPULATION PHARMACOKINETICS OF HIGH-DOSE, EXTENDED-INTERVAL AMIKACIN IN CRITICALLY ILL CHILDREN
    Thompson, R. Zachary
    Wysocki, Emma
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 430 - 430
  • [33] AN EVALUATION OF POINT AND INTERVAL ESTIMATES IN POPULATION PHARMACOKINETICS USING NONMEM ANALYSIS
    WHITE, DB
    WALAWANDER, CA
    TUNG, Y
    GRASELA, TH
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (01): : 87 - 112
  • [34] Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation
    Li, Ze
    Yang, Siyu
    Hua, Zixin
    Lu, Yanxia
    Li, Xingang
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (05) : 3351 - 3362
  • [35] Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study
    Lee, C.
    Walker, S. A. N.
    Walker, S. E.
    Seto, W.
    Simor, S.
    Cartotto, R.
    Jeschke, M.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2016, 69 (01): : 81 - 81
  • [36] Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation
    Ze Li
    Siyu Yang
    Zixin Hua
    Yanxia Lu
    Xingang Li
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 3351 - 3362
  • [37] The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study
    Bourguignon, Laurent
    Ducher, Michel
    Matanza, David
    Bleyzac, Nathalie
    Uhart, Mathieu
    Odouard, Emmanuel
    Maire, Pascal
    Goutelle, Sylvain
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 (02) : 279 - 285
  • [38] A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate
    Wu, Qier
    Peters, Sheila Annie
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (04): : 220 - 229
  • [39] Natalizumab extended-interval dosing is associated with subtle inflammatory changes: a proof of concept study
    Pisa, Marco
    Croese, Tommaso
    Congiu, Martina
    Dalla Costa, Gloria
    Gelibter, Stefano
    Orrico, Mario
    Moiola, Lucia
    Comi, Giancarlo
    Furlan, Roberto
    Leocani, Letizia
    NEUROLOGY, 2021, 96 (15)
  • [40] Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study
    Langan, Katherine M.
    Jacob, Jovan
    Li, Jian
    Nation, Roger L.
    Bellomo, Rinaldo
    Howden, Benjamin
    Johnson, Paul D. R.
    CRITICAL CARE AND RESUSCITATION, 2014, 16 (03) : 190 - 196
12345